Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jan 6;7(1):242-249.
doi: 10.1002/lio2.729. eCollection 2022 Feb.

Bisphosphonate therapy in otosclerosis: A scoping review

Affiliations

Bisphosphonate therapy in otosclerosis: A scoping review

René E Zimmerer et al. Laryngoscope Investig Otolaryngol. .

Abstract

Objective: Otosclerosis, a leading cause of deafness in adults, results from defective bone remodeling of the otic capsule. Bisphosphonates have been used to decrease bone remolding in many diseases, including otosclerosis. This study analyzes whether current literature supports bisphosphonate therapy as an effective treatment for otosclerosis.

Design: Scoping review.

Methods: A search was performed in three electronic databases; PubMed, Scopus, and Cochrane Control Trials. Articles were screened independently by two masked reviewers based on prespecified inclusion and exclusion criteria. After unmasking, the two reviewers resolved discrepancies through discussion.

Results: From the search, 35 unique articles were identified for analysis. The dates of these publications range from 1982 to 2018. Further title and full-text review identified six articles for inclusion in this review. Three of the studies included are randomized controlled trials (RCT)s, and three are retrospective case reviews. These studies analyzed bisphosphonate therapy regimens, but dose and study length varied, making direct comparisons difficult. Only one RCT study was able to show a statistically significant change between patients treated with bisphosphonates compared to a control group.

Conclusions: The efficacy of bisphosphonates for halting bone remodeling in otosclerosis remains unclear. Reviewing the literature, we found significant variations in experimental design and few studies of high-level evidence. Future RCTs investigating therapies for otosclerosis are needed before a firm conclusion about bisphosphonates efficacy as a pharmacological treatment of otosclerosis.Level of Evidence: 3a.

Keywords: Otosclerosis; bisphosphonates; hearing loss; otospongiosis; scoping review.

PubMed Disclaimer

Conflict of interest statement

The authors declare no potential conflict of interest.

Figures

FIGURE 1
FIGURE 1
Middle ear anatomy
FIGURE 2
FIGURE 2
PRISMA diagram

Similar articles

Cited by

References

    1. Moore KL. Before We Are Born: Essentials of Embryology and Birth Defects. 10th ed. Elsevier; 2020.
    1. Liktor B, Szekanecz Z, Batta TJ, Sziklai I, Karosi T. Perspectives of pharmacological treatment in otosclerosis. Eur Arch Otorhinolaryngol. 2013;270(3):793‐804. doi:10.1007/s00405-012-2126-0 - DOI - PubMed
    1. Declau F, Spaendonck MV, Timmermans JP, et al. Prevalence of histologic otosclerosis: an unbiased temporal bone study in Caucasians. Adv Otorhinolaryngol. 2007;65:6‐16. doi:10.1159/000098663 - DOI - PubMed
    1. Causse JR, Causse JB, Bretlau P, et al. Etiology of otospongiotic sensorineural losses. Am J Otol. 1989;10(2):99‐107. - PubMed
    1. Ishai R, Halpin CF, Shin JJ, McKenna MJ, Quesnel AM. Long‐term incidence and degree of sensorineural hearing loss in otosclerosis. Otol Neurotol. 2016;37(10):1489‐1496. doi:10.1097/MAO.0000000000001234 - DOI - PubMed

Publication types

LinkOut - more resources